Open Menu

Meetings & Education

Meetings & Education

Research & Data

Practice & Patients

Career Development

News & Initiatives

Get Involved

Trial in progress: A phase Ib/II study to evaluate the safety and efficacy of atezolizumab plus bevacizumab as adjuvant therapy following carbon ion radiotherapy in hepatocellular carcinoma (VANGUARD trial).

download

Background: While hepatic resection remains the standard curative treatment for hepatocellular carcinoma (HCC), many cases are ineligible due to impaired liver function or patient-related factors. Percutaneous ablation is an option for small HCC but is limited by tumor size. Carbon ion radiotherapy (C-ion RT) has emerged as a promising modality, characterized by superior biological efficacy and dose distribution compared to conventional radiotherapy. Although HCC is relatively radiosensitive, conventional radiotherapy has limited efficacy due to low radiation tolerance of surrounding liver tissue. C-ion RT achieves effective treatment while minimizing radiation exposure through the superior dose localization of the carbon ion beam’s Bragg peak. The establishment of adjuvant systemic therapy to prevent recurrence remains an urgent unmet need in HCC management. The IMbrave050 trial demonstrated the efficacy of combined atezolizumab and bevacizumab （Atezo+Bev）after resection or ablation, but recent analyses suggest diminishing long-term benefits. The combination of immune checkpoint inhibitors (ICIs) and radiotherapy has shown promise in several malignancies, with preclinical studies demonstrating synergistic enhancement of ICI efficacy through radiation-induced immunogenic cell death. Additionally, carbon ion radiation induces stronger immune responses compared to proton therapy. Based on these findings, we designed a phase Ib/II study to evaluate sequential C-ion RT followed by ICI as a novel therapeutic approach.

Methods: This multicenter, open-label, single-arm phase Ib/II study evaluates the safety and efficacy of Atezo+Bev as adjuvant therapy following C-ion RT for HCC. Key inclusion criteria include treatment-naïve, Child-Pugh class A, maximum intrahepatic tumor diameter ≥4 cm and ≤3 intrahepatic tumors. After initial enrollment, patients undergo C-ion RT followed by a two-week observation period with eligibility screening for second enrollment. Eligible patients receive atezolizumab (1200 mg) and bevacizumab (15 mg/kg) every 3 weeks for up to 48 weeks, with radiological assessments every 3 months. The Phase Ib part will enroll six patients to evaluate dose-limiting toxicities. Secondary endpoints include adverse events (AEs) and serious AEs for safety and 1-year RFS, overall survival (OS) and 6-month OS rates for efficacy. If tolerability is confirmed, the trial will proceed to Phase II. Clinical trial information: jRCT2031240284.

Disclaimer

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Author Details

Keisuke Koroki

Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan

Authors chevron_right

Associated Organizations chevron_right

Abstract Details

Meeting

2025 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

View MoreAbstract Disclosure
open_in_new

Similar Abstracts

text_snippet

Abstract

2023 ASCO Annual Meeting

Efficacy, safety and patient reported outcomes (PROs) from the phase III IMbrave050 trial of adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation.

First Author: Masatoshi Kudo

text_snippet

Abstract

2023 ASCO Annual Meeting

Results from the MORPHEUS-liver study: Phase Ib/II randomized evaluation of tiragolumab (tira) in combination with atezolizumab (atezo) and bevacizumab (bev) in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (uHCC).

First Author: Richard S. Finn

text_snippet

Abstract

2023 ASCO Gastrointestinal Cancers Symposium

IMbrave150: Exploratory analysis to examine the association between bevacizumab (bev) ever being skipped and bev never being skipped in patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab (atezo) + bev in a global phase 3 study.

First Author: Masatoshi Kudo

text_snippet

Abstract

2024 ASCO Gastrointestinal Cancers Symposium

Evaluating the safety and efficacy of the addition of liver radiation (RT) to atezolizumab and bevacizumab (A/B) in advanced hepatocellular carcinoma (HCC): A retrospective cohort analysis.

First Author: Timothy J. Brown

iframe

Download

Your Privacy

ASCO is committed to transparency regarding our websites and the ways we process data. When you visit our site, we may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences, your location, or your device and is mostly used to make the site work as you expect it to and to personalize your web experience with us.

Because we respect your right to privacy, you can choose not to allow some or all types of cookies. Click on the different category headings to find out more about the types of cookies used on our websites and change your default settings to match your preferences. Please read these carefully. Blocking some types of cookies may impact your experience on the site, including our ability to personalize the content you receive from us.

For a full explanation of the personal and non-personal information we collect on our site, including how we use that information and your rights regarding that information, please review our Privacy Policy. Use of our website is also subject to our Terms of Use.

Allow All

Manage Consent Preferences

Essential Website Cookies

Always Active

These cookies are necessary for the website to function and are sometimes referred to as “strictly necessary” cookies. They make sure the website delivers you information and services in an optimal way.

They are often set in response to an action you take, such as changing your cookie preferences, setting your privacy preferences, logging in to our website, asking the site to remember you on subsequent pages, or filling in forms. These cookies do not identify you personally.

You can set your browser to block or alert you about all cookies, including essential website cookies, but some parts of the site will not work as a result.

Cookies Details‎

Performance and Functionality Cookies

Performance and Functionality Cookies

These cookies enhance the performance and functionality of our websites and the services we provide. For example, these cookies can keep track of your visitor session in between visits, enable you to share content through social media, use embedded media players, and use comment features. They also help us balance website load and improve site speed and performance.

All information these cookies collect is aggregated and therefore anonymous. These cookies may be set by us or by third party providers whose services we have added to our websites. These cookies are non-essential, but without these cookies, certain functionality or enhanced features may become unavailable.

Cookies Details‎

Personalization and Analytics Cookies

Personalization and Analytics Cookies

These cookies collect information that is used to help us understand how our websites and content are used, help us customize our websites and application for you in order to enhance your experience, and help us improve the content that ASCO creates to better meet our members’ and visitors’ needs. Examples include cookies that show us which content might be most popular with our visitors, understand browsing history of our users, understand the effectiveness of our own advertising, and enable us to recommend content to individual users based on their profile and activities on the website.

These cookies may be set by us or by third party providers whose services we have added to our websites.

These cookies are non-essential to the functionality of the site and may contain information that enables us or our third party providers to identify you and build a profile of your interests. Without these cookies, you will not be able to have a customized or personalized experience within our website.

Cookies Details‎

Advertising Cookies and Social Media Cookies

Advertising Cookies and Social Media Cookies

Advertising (or Targeting) cookies are third party cookies that may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant ads on other sites.

Social Media Cookies are cookies set by a range of social media services that we have added to the site to enable you to share our content with your friends and networks. They are capable of tracking your activities across other sites and building a profile of your interests. This may impact the content and messages you see on other websites you visit.

These cookies and the data collected by the third parties may be combined with data from other users or data about your activity on other sites. While the data collected on our site is aggregate or non-personal, the data may be used by such third parties to link you on other platforms or otherwise identify you.

If you do not allow these cookies, you may experience less targeted advertising.

Cookies Details‎

Back Button

Cookie List

Search Icon

Filter Icon

Clear

checkbox labellabel

ApplyCancel

ConsentLeg.Interest

checkbox labellabel

checkbox labellabel

checkbox labellabel

• View Cookies

• Name

cookie name

Save Settings